

# Maurice P H M Jansen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7783518/publications.pdf>

Version: 2024-02-01

38  
papers

2,083  
citations

304743

22  
h-index

361022

35  
g-index

40  
all docs

40  
docs citations

40  
times ranked

3747  
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular Classification of Tamoxifen-Resistant Breast Carcinomas by Gene Expression Profiling. <i>Journal of Clinical Oncology</i> , 2005, 23, 732-740.	1.6	322
2	Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. <i>BMC Genomics</i> , 2008, 9, 239.	2.8	300
3	Association of an Extracellular Matrix Gene Cluster with Breast Cancer Prognosis and Endocrine Therapy Response. <i>Clinical Cancer Research</i> , 2008, 14, 5555-5564.	7.0	155
4	Molecular profiling of platinum resistant ovarian cancer. <i>International Journal of Cancer</i> , 2006, 118, 1963-1971.	5.1	139
5	Application of circulating tumor DNA in prospective clinical oncology trials – standardization of preanalytical conditions. <i>Molecular Oncology</i> , 2017, 11, 295-304.	4.6	123
6	HOXB13-to-IL17BR Expression Ratio Is Related With Tumor Aggressiveness and Response to Tamoxifen of Recurrent Breast Cancer: A Retrospective Study. <i>Journal of Clinical Oncology</i> , 2007, 25, 662-668.	1.6	118
7	Hallmarks of Aromatase Inhibitor Drug Resistance Revealed by Epigenetic Profiling in Breast Cancer. <i>Cancer Research</i> , 2013, 73, 6632-6641.	0.9	79
8	Pathway analysis of gene lists associated with platinum-based chemotherapy resistance in ovarian cancer: The big picture. <i>Gynecologic Oncology</i> , 2010, 117, 170-176.	1.4	76
9	Three Hsp70 Genes Are Located in the C4-H-2D Region: Possible Candidates for the Orch-1 Locus. <i>Genomics</i> , 1993, 15, 350-356.	2.9	65
10	Decreased expression of ABAT and STC2 hallmarks ER $\alpha$ -positive inflammatory breast cancer and endocrine therapy resistance in advanced disease. <i>Molecular Oncology</i> , 2015, 9, 1218-1233.	4.6	64
11	Somatic mutation detection using various targeted detection assays in paired samples of circulating tumor DNA, primary tumor and metastases from patients undergoing resection of colorectal liver metastases. <i>Molecular Oncology</i> , 2016, 10, 1575-1584.	4.6	61
12	Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen. <i>Breast Cancer Research and Treatment</i> , 2009, 113, 275-283.	2.5	56
13	Estrogen receptor mutations and splice variants determined in liquid biopsies from metastatic breast cancer patients. <i>Molecular Oncology</i> , 2018, 12, 48-57.	4.6	52
14	Integrated genomics of chemotherapy resistant ovarian cancer: A role for extracellular matrix, TGF $\beta$ and regulating microRNAs. <i>International Journal of Biochemistry and Cell Biology</i> , 2010, 42, 25-30.	2.8	49
15	Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen. <i>Breast Cancer Research and Treatment</i> , 2013, 139, 39-49.	2.5	49
16	High-throughput isolation of circulating tumor DNA: a comparison of automated platforms. <i>Molecular Oncology</i> , 2019, 13, 392-402.	4.6	37
17	Downregulation of SIAH2, an ubiquitin E3 ligase, is associated with resistance to endocrine therapy in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2009, 116, 263-271.	2.5	35
18	<i>RAS</i> and <i>BRAF</i> mutations in cell-free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue-tested <i>RAS</i> wild-type advanced colorectal cancer. <i>Molecular Oncology</i> , 2019, 13, 2361-2374.	4.6	32

#	ARTICLE	IF	CITATIONS
19	Cell-free DNA mutations as biomarkers in breast cancer patients receiving tamoxifen. <i>Oncotarget</i> , 2016, 7, 43412-43418.	1.8	30
20	Comparison of variant allele frequency and number of mutant molecules as units of measurement for circulating tumor DNA. <i>Molecular Oncology</i> , 2021, 15, 57-66.	4.6	28
21	An 8-gene mRNA expression profile in circulating tumor cells predicts response to aromatase inhibitors in metastatic breast cancer patients. <i>BMC Cancer</i> , 2016, 16, 123.	2.6	25
22	Protein Kinase A-induced tamoxifen resistance is mediated by anchoring protein AKAP13. <i>BMC Cancer</i> , 2015, 15, 588.	2.6	24
23	LRG1 mRNA expression in breast cancer associates with PIK3CA genotype and with aromatase inhibitor therapy outcome. <i>Molecular Oncology</i> , 2016, 10, 1363-1373.	4.6	23
24	TP53 Mutations in Serum Circulating Cell-Free Tumor DNA As Longitudinal Biomarker for High-Grade Serous Ovarian Cancer. <i>Biomolecules</i> , 2020, 10, 415.	4.0	23
25	Detection of tumor-derived extracellular vesicles in plasma from patients with solid cancer. <i>BMC Cancer</i> , 2021, 21, 315.	2.6	18
26	An Optimized Workflow to Evaluate Estrogen Receptor Gene Mutations in Small Amounts of Cell-Free DNA. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 123-137.	2.8	15
27	High ctDNA molecule numbers relate with poor outcome in advanced ER+, HER2 <sup>-</sup> postmenopausal breast cancer patients treated with everolimus and exemestane. <i>Molecular Oncology</i> , 2020, 14, 490-503.	4.6	14
28	Optimizing Nanopore sequencing-based detection of structural variants enables individualized circulating tumor DNA-based disease monitoring in cancer patients. <i>Genome Medicine</i> , 2021, 13, 86.	8.2	14
29	Liquid biopsy in esophageal cancer: a case report of false-positive circulating tumor DNA detection due to clonal hematopoiesis. <i>Annals of Translational Medicine</i> , 2021, 9, 1264-1264.	1.7	12
30	Re: Limits of Predictive Models Using Microarray Data for Breast Cancer Clinical Treatment Outcome. <i>Journal of the National Cancer Institute</i> , 2005, 97, 1851-1852.	6.3	10
31	Dutch National Round Robin Trial on Plasma-Derived Circulating Cell-Free DNA Extraction Methods Routinely Used in Clinical Pathology for Molecular Tumor Profiling. <i>Clinical Chemistry</i> , 2022, 68, 963-972.	3.2	10
32	The prognostic and predictive value of ESR1 fusion gene transcripts in primary breast cancer. <i>BMC Cancer</i> , 2022, 22, 165.	2.6	8
33	Somatic Tumor Mutations Detected by Targeted Next Generation Sequencing in Minute Amounts of Serum-Derived Cell-Free DNA. <i>Scientific Reports</i> , 2017, 7, 2136.	3.3	7
34	Increased MAPK1/3 Phosphorylation in Luminal Breast Cancer Related with PIK3CA Hotspot Mutations and Prognosis. <i>Translational Oncology</i> , 2017, 10, 854-866.	3.7	5
35	SIAH2 protein expression in breast cancer is inversely related with ER status and outcome to tamoxifen therapy. <i>American Journal of Cancer Research</i> , 2016, 6, 270-84.	1.4	5
36	In reply to the letter by Gevaert et al.. <i>International Journal of Cancer</i> , 2006, 119, 1512-1512.	5.1	0

#	ARTICLE	IF	CITATIONS
37	mRNA expression profiles in circulating tumor cells (CTCs) of patients with metastatic breast cancer (MBC) treated with aromatase inhibitors (AI).. Journal of Clinical Oncology, 2013, 31, 11045-11045.	1.6	0
38	The COMPLETE trial: Holistic early response assessment for oropharyngeal cancer patients; Protocol for an observational study. BMJ Open, 2022, 12, e059345.	1.9	0